PubMed Health⌕ Search

Biomedical subjects

R Triau

Publications and source records attributed to R Triau.

At least 19 recordsLinked to original sources
PubMed1989

[Serological evaluation of an antimeningococcal mass vaccination campaign in Niger].

Authors searched by mean of radio-immuno-essay A and C anti-meningococcal antibodies in two villages from Niger (181 and 92 patients) in a meningitidis endemic area, which one profited 10 months ago of a mass vaccination campaign (A and C polysaccharides). A and C antibodies quantities and percentages of protected patients are not significantly different between the two villages. In one hand anti-C levels increase with patients age. In the other hand, there is a correlation between C meningococcal antibodies and anti-Hbc antibodies.

Adolescent↗
PubMed1988

[20 years' use of the diphtheria-pertussis-tetanus vaccine].

Between 1966 and 1982, a triple DPT vaccine was studied in France in 1,871 infants between the ages of 3 and 5 months. The study covered tolerance and serological efficacy of two immunization schedules using 2 or 3 initial injections. Computerized analysis of the 877 complete files showed satisfactory tolerance of this association and the serological efficacy of 2 initial doses of tetanus and diphtheria vaccines. Pertussis immunization is only effective after 3 injections. The presence of maternal antibodies when the first injection is given only decreases the immune response of diphtheria vaccine.

Antibodies, Viral↗
PubMed1983

Antibodies to meningococcus polysaccharides in nonspecific gamma-globulins from different regions of the world.

Seventy-one batches of nonspecific gamma-globulin obtained from France, USSR and Mongolia were studied for presence of specific antibody to group A and C meningococcus polysaccharide. Specific activity was tested by two methods: radioimmunoassay (Lyon) and reaction of passive haemagglutination inhibition (Moscow). Antibodies were detected in all the gamma-globulin batches tested, in some of them at high titres. The summary results indicated that approximately equal levels of specific A antibodies were present in preparations obtained from the different regions of the world. Antibodies to group C polysaccharide showed considerable variation in level from selection country to country; the highest level of C antibodies was in gamma-globulin from France. The authors feel entitled by the results to recommend testing of nonspecific gamma-globulin, selection of batches with a high level of specific antimeningococcus antibodies, and their judicious use.

Antibodies, Bacterial↗
PubMed1978

Combination of attenuated measles vaccine (Schwarz) with meningococcus A and A + C vaccine.

There is an obvious interest in a combined meningococcus-measles vaccine since the two diseases are widespread and serious in Third World countries among children under five years of age. The purpose of our study was to show the safety and effectiveness of such a combined preparation. The study covered 110 children between 8 months and 4 years of age who were followed systematically in a maternal child health center in the Paris area. Only 93 of them were checked before and after the immunization. The serologic titrations by the hemagglutination assay (IHA) for measles, and by radioimmunological assay (RIA) for meningococcus A and C showed that the Schwarz strain measles vaccine combined with meningococcus A or the association A+C does not interfere with the increase of A or C titers. 100% of the children showed a seroconversion equal to or less than 2 micrograms per ml, in the case of meningococcus A, as well as for C, regardless of age. Furthermore, 88% of the subjects showed a titer greater than or equal to 4 micrograms for the meningococcus A and 79% for C. On the other hand, meningococcus A or the association A+C seem to depress measles vaccine activity. Nevertheless, more than 80% of the children tested showed seroconversion when the measles vaccine was combined with meningococcus A, and only 69% when combined with meningococcus A and C.

Age Factors↗
PubMed1978

[Results of preventive rabies vaccination with a concentrated vaccine of the PM/WI38-1503-3M rabies strain cultured on human diploid cells. Preparation of mixed antirabies-antitetanus hyperimmune immunoglobulin by plasmapheresis of blood taken from vaccinated veterinary students].

Many thousands of people in France and abroad have already benefited from preventive rabies vaccination by means of a vaccine obtained from culture on human diploid cells, perfected ten years ago by R. Lang, the Institut Mérieux and the Wistar Institute. In addition to being well tolerated, the serological efficacy of this vaccine is such that 100% of the vaccines observed had a seroconversion after only two injections at an interval of one month. However, a booster dose should be given 6 to 12 months after the first injection, and a further booster 3 to 5 years later or on request in case of known contamination. These boosters, combined with an anti-tetanus booster, induce such high antibody titers--between 10-100 and even 1000 I.U./ml--that it is easy to obtain substantial batches of combined anti-rabies and anti-tetanus immunoglobulin from a small number of volunteers. The complete efficacy of this new vaccine reduces the number of systematic post-vaccinal serologic controls and its innocuity is such that an extended preventive vaccination programme may be carried out, for instance in the case of children living in areas known to be dangerous.

Adult↗
PubMed1978

Killed poliovirus antigen titration in humans.

To establish the antigen content of a killed poliovirus vaccine sufficiently potent to induce immunity with one or two doses and to establish a reference standard vaccine which has been tested under field conditions, a titration was carried out in infants to determine the amount of each of the three antigenic types of poliovirus vaccine required to induce seroconversion with a single dose. It has been observed that over a critical range of antigen concentration there is an essentially linear relationship between antibody response and quantity of antigen administered. More than 90 percent of the groups studied had detectable antibody after receiving single injections of 80, 8 and 64 D-antigen units of Types I, II and III, respectively. Four-fold less antigen for each of the three types was less effective. The implications of these findings for an efficient immunization procedure are discussed.

Antibodies, Viral↗
PubMed1973

A controlled field trial of a serogroup A meningococcal polysaccharide vaccine.

A controlled field trial of a serogroup A meningococcal polysaccharide vaccine was conducted at three locations in Egypt during the winter cerebrospinal meningitis (CSM) season of 1971-72. The study population consisted of schoolchildren 6-15 years of age. No cases of serogroup A meningococcal CSM occurred in the group of students vaccinated with the test vaccine whereas 8 cases occurred in the control group vaccinated with tetanus toxoid, and 151 cases occurred in an unvaccinated contrast group. The case rate was significantly different between the test and control groups as well as between the test and contrast groups but was similar between the control and contrast groups. The previously demonstrated safety of the vaccine was confirmed. A significant serological response was elicited in the majority of the vaccinated students.

Adolescent↗